UCLA Health’s Outpatient Theranostics Center allows clinicians to treat up to 16 patients per day with Pluvicto and other medicines. A dedicated clinical research team of about 20 staff members supports the more than one dozen active theranostics clinical trials currently in progress at the health system.

A Food and Drug Administration project to promote diversity in clinical studies of cancer treatments was removed from the agency's website, as the Trump administration halts DEI initiatives.

Just a few weeks ago on January 15, the Food and Drug Administration (FDA) under the Biden administration revoked authorization of the additive red dye 3, meaning it will be banned from foods and drugs.

The FDA clearance aids AstraZeneca and Daiichi Sankyo’s plan to position ADCs like Enhertu ahead of chemotherapy in a variety of tumors.

Research that has not yet been peer-reviewed shows the newest blood test is more than 80% accurate in detecting colon cancer in people who had the disease. The test is 90% accurate in ruling out cancer in healthy adults, according to the study published Monday in the Journal of Clinical Oncology.

During Donald Trump's draconian first-week rollbacks, cancer research and other crucial medical projects have been paused indefinitely.

Astra is due to pay Daiichi US$175 million in milestones after the US approval, the companies said. Enhertu is cleared in the US and European Union for some breast cancer patients whose cancer spread after receiving treatment, or whose disease returned after surgery.

The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of breast cancer, the health regulator said on Friday.

Studies going back decades have shown a potential link between artificial food dyes and attention deficit hyperactivity disorder symptoms in kids.

Over 35 years after the first study linking the artificial food dye Red 3 to thyroid cancer in rats was published, the U.S. is beginning to phase it out of foods and drugs.

The U.S. Food and Drug Administration wants to put nutrition information front and center on food products to give consumers an easier way to identify nutrients linked to chronic diseases. The FDA announced its plans to push for a rule that would require food manufacturers to include a front-of-package nutrition label on most packaged food products.

Enhertu is a HER2-directed antibody and topoisomerase inhibitor conjugate. Approval of the new indication was based on data from the phase 3 DESTINY-Breast06 trial (ClinicalTrials.gov Identifier: NCT04494425 ).